Antibody responses post-booster covid-19 vaccination: insights from a single-center prospective cohort study

Basit Öğe Kaydı
dc.authorid0000-0001-7275-8724
dc.contributor.authorDinç, Harika Öykü
dc.contributor.authorCan, Günay
dc.contributor.authorBudak, Beyhan
dc.contributor.authorDaşdemir, Ferhat Osman
dc.contributor.authorKeskin, Elif
dc.contributor.authorKırkoyun Uysal, Hayriye
dc.contributor.authorAydoğan, Okan
dc.contributor.authorBalkan, İlker İnanç
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorErgin, Sevgi
dc.contributor.authorSaltoğlu, Neşe
dc.contributor.authorKocazeybek, Bekir
dc.date.accessioned2024-09-18T12:37:01Z
dc.date.available2024-09-18T12:37:01Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractThe study aimed to evaluate the effect of booster dose COVID-19 vaccines on prevention and humoral immune response in individuals with different vaccination schemes during the period BA.4 and BA.5 omicron sub-variants were globally dominant. The study included 146 individuals who preferred different vaccination schemes for booster doses. Anti-spike/RBD-IgG and neutralizing antibody levels were measured 28 days after the booster dose vaccination upon their consent. There is no significant difference between median antibody titers detected according to different vaccination schemes. SARS-CoV-2 neutralizing antibody inhibition percentages were detected significantly higher in serum samples before and after the last booster dose in 2 BNT162b2+1 BNT162b2(99.42 %), 2 BNT162b2 + 2 BNT162b2(99.42 %), and 2 BNT162b2 + 3 BNT162b2(99.42 %) vaccination schemes (p = 0.004, p = 0.044, p = 0.002,respectively). The study indicated that a booster vaccination dose provides a high level of protection against severe COVID-19 and death. We think that the variant-specific pancoronavirus vaccines will be necessary to protect against breakthrough infections.
dc.description.sponsorshipIU-Cerrahpasa Scientific Research Projects Uniten_US
dc.identifier.citationDinç, H. Ö., Can, G., Budak, B., Daşdemir, F. O., Keskin, E., Kırkoyun Uysal, H. ... Kocazeybek, B. (2024). Antibody responses post-booster covid-19 vaccination: insights from a single-center prospective cohort study. Diagnostic Microbiology and Infectious Disease, 110(2). http://dx.doi.org/10.1016/j.diagmicrobio.2024.116425
dc.identifier.doi10.1016/j.diagmicrobio.2024.116425
dc.identifier.issn0732-8893
dc.identifier.issn1879-0070
dc.identifier.issue2
dc.identifier.pmid39098282
dc.identifier.scopus2-s2.0-85200217593
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1016/j.diagmicrobio.2024.116425
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12809
dc.identifier.volume110
dc.identifier.wos001288939000001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAydoğan, Okan
dc.language.isoen
dc.relation.ecinfo:eu-repo/grantAgreement/EC/FP7/36992
dc.relation.ispartofDiagnostic Microbiology and Infectious Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntibody
dc.subjectBNT162b2
dc.subjectCoronaVac
dc.subjectCOVID-19
dc.subjectOmicron
dc.titleAntibody responses post-booster covid-19 vaccination: insights from a single-center prospective cohort study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Aydoğan-Okan-2024.pdf
Boyut:
574.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu